Debiopharm signs diabetes deal with Mercury
This article was originally published in Scrip
Executive Summary
Debiopharm and the US biotech company Mercury Therapeutics have signed an exclusive licence agreement for the development and commercialisation of the Swiss company's Debio 0930.